Skip to main content
Equibles
QUCY logo

QUCY · Quantum Cyber N.V. · Metrics

Track QUCY — free

Use QUCY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research QUCY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.08 +0.01 (+0.93%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has incurred recurring losses from operations and does not yet have an established source of revenues sufficient to cover its operating costs. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management evaluated conditions and events that raise substantial doubt and the Company's plans to mitigate those conditions over the one-year look-forward period from the date these consolidated financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$89.95M
Shares
84.07M
Volume · Oct 20 195K Avg daily vol (3M) 668.4K

QUCY metrics

69 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.07
Market cap
$89.95M

Price action

20 metrics
Price change (1W)
+3.9%
Price change (30D)
-17.7%
Price change (3M)
-7.8%
Price change (6M)
+127.2%
Price change (YTD)
-4.5%
Price change (1Y)
-28.2%
Trailing year
Price change (5Y)
—
52-week high
$3.56
52-week low
$0.32
Change from 52-week high
-69.9%
Change from 52-week low
+231.3%
Annualized volatility
357.5%
Annualized volatility (3M)
94.6%
Beta
3.9
RSI (14D)
38.5
Price vs SMA 50
-20.6%
Price vs SMA 200
-12.4%
Avg volume (3M)
668,387
Relative volume
0.5
Average dollar volume
$903,184

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
84.07M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
90.7×
reciprocal yield 1.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
99.5×
reciprocal yield 1.0%
P / book
4.4
reciprocal yield 22.9%
FCF yield
-16.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-26.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
72.6%
Operating margin
-3,005.0%
Trailing 12 months
Net margin
-3,018.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$24.12M
Net income (TTM)
−$23.83M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.07

Growth

11 metrics
Revenue growth YoY
+140.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$895,479
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+308.5%
Year over year · more shares
Revenue CAGR (3Y)
+0.5%
Revenue CAGR (5Y)
+1.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-117.0%
Return on assets
-102.0%
Debt / equity
1.5
Current ratio
5.6
EBITDA (TTM)
−$23.77M
Free cash flow (TTM)
−$14.39M
Quick ratio
—
Interest coverage
-79.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$67,811
Latest balance sheet
Cash & equivalents
$13.40M
Total assets
$23.37M
Total debt
$956,902

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$14.25M
Capital expenditures (TTM)
$137,457
R&D (TTM)
$9.30M
SG&A (TTM)
—
Stock compensation (TTM)
$103,415
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
18
13F filer change QoQ
0
Institutional ownership
0.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
1.0%
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
-27.6%
Holder tenure
3.8
Price vs estimated holder cost
+9.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
1.9%
Latest settlement · 5.5 days to cover
Days to cover
5.5d
Short-squeeze score
51 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1874252 CUSIP N5436L119 13F (30d) 3 filings 3 filers Visit website Investor relations